Clinical Trials Directory

Trials / Completed

CompletedNCT06227195

Mechanism of IL-10 Pathway-mediated Regulatory B Cell Dysfunction in Osteoarthritis

Status
Completed
Phase
Study type
Observational
Enrollment
40 (actual)
Sponsor
Shufeng Li · Academic / Other
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Our previous work has shown that Treg function is impaired in OA patients, but the cause of Treg deficiency has not been investigated. Since Breg has been shown to promote Treg differentiation and tissue repair, it is highly likely that the absence of the immunomodulatory effect of Breg in OA patients leads to impaired Treg differentiation. Based on the above data, we hypothesized that Breg plays a protective role in the course of OA by regulating T cell composition and promoting Treg differentiation through the secretion of anti-inflammatory factor IL-10

Conditions

Timeline

Start date
2019-01-01
Primary completion
2021-12-31
Completion
2021-12-31
First posted
2024-01-26
Last updated
2024-01-26

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06227195. Inclusion in this directory is not an endorsement.

Mechanism of IL-10 Pathway-mediated Regulatory B Cell Dysfunction in Osteoarthritis (NCT06227195) · Clinical Trials Directory